Syndax Pharmaceuticals Inc. Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
5/14/2013 10:06:02 AM
More...
|
Syndax Pharmaceuticals Inc. to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at American Society of Clinical Oncology
5/29/2012 12:40:58 PM
More...
|
Syndax Pharmaceuticals Inc. Appoints Luke Evnin, Ph.D. to Board of Directors
5/16/2012 12:30:48 PM
More...
|
Syndax Pharmaceuticals Inc. Announces Publication of Entinostat Phase 2 Clinical Trial Data in Journal of Clinical Oncology
4/30/2012 11:24:42 AM
More...
|
Syndax Pharmaceuticals Inc. Appoints Arlene Morris as CEO
4/18/2012 8:39:41 AM
More...
|
Syndax Pharmaceuticals Inc. Announces Start of Phase 1/2 Study of Entinostat in Combination With Lapatinib in HER2-Positive Metastatic Breast Cancer
4/9/2012 6:51:35 AM
More...
|
Syndax Pharmaceuticals Inc. Appoints Arthur M. Pappas to Board of Directors
4/5/2012 9:55:51 AM
More...
|
Syndax Pharmaceuticals Inc. to Present at Upcoming Conferences
3/29/2012 10:58:33 AM
More...
|
Syndax Pharmaceuticals Inc. Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models
2/9/2012 10:29:02 AM
More...
|
Syndax Pharmaceuticals Inc. to Present at Upcoming Conferences
2/7/2012 10:53:53 AM
More...
|
|